CompletedEUCTR 2011-004668-31
A Phase 3, Open-label, Multicentre, Protocol to Provide Access to Guanfacine Hydrochloride Extended Release for European Subjects with Attention-deficit/Hyperactivity Disorder (ADHD) who Participat...
This historical record does not confirm current site availability.
Historical research recordMultiple countries
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with ADHD. Other eligibility criteria applied.
- Listed locations
- Austria · Belgium and 8 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 249
- Sponsor
- Shire Pharmaceutical Development Ltd
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United Kingdom, Belgium, Austria, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2011-004668-31
- Official title
Show the full official title
A Phase 3, Open-label, Multicentre, Protocol to Provide Access to Guanfacine Hydrochloride Extended Release for European Subjects with Attention-deficit/Hyperactivity Disorder (ADHD) who Participat...
Get this study by email
Recruitment & locations
CompletedAustria · Belgium · Germany
7 more locations
- Ireland
- Italy
- Netherlands
- Poland
- Spain
- Sweden
- United Kingdom
Registry details
Historical country statuses
- Austria — Completed
- Belgium — Completed
- Germany — Completed
- Spain — Completed
- United Kingdom — Completed
- Ireland — Completed
- Italy — Completed
- Netherlands — Completed
- Poland — Completed
- Sweden — Completed
Questions about this study
Who is behind this study?
The study sponsor is Shire Pharmaceutical Development Ltd, a pharmaceutical company.
Who was this study for?
This study was for people with ADHD. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...